Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986533 in Healthy Participants, an Open-label Assessment of Food and pH Effects on the Relative Bioavailability of BMS-986533, and an Open-label Study to Evaluate P-gp- and BCRP-mediated Drug-Drug Interaction Potential of BMS-986533 in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Recruiting
- Celerion Coorporate Office Nebraska
-
Contact:
- Allen Hunt, Site 0001
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must have a body mass index (BMI) of 18 to 32.44 kg/m2, inclusive, and total body weight ≥ 50 kg.
- Female (as assigned at birth) participants who are not of childbearing potential must have documented proof of reproductive status.
- A male (as assigned at birth) who is sexually active with IOCBP must agree to follow instructions for method(s) of contraception as described and included in the ICF.
Exclusion Criteria:
- Participants must not have presence or history of any clinically relevant abnormality, condition, or disease of renal, hepatic, hematologic, GI, endocrine, pulmonary, neurologic, or immunologic (including history of angioedema or hypersensitivity reactions to medication).
- Participants must not have current or recent (within 3 months of study intervention administration) clinically significant GI disease.
- Participants must not have any major surgery within 3 months of study intervention administration.
- Participants must not have Any surgical or medical intervention that could possibly affect ADME of study intervention (eg, bariatric surgery, GI surgery).
- Other protocol defined inclusion/exclusion criteria applies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A
|
Specified dose on specified days
Specified dose on specified days
|
|
Experimental: Arm B
|
Specified dose on specified days
Specified dose on specified days
|
|
Experimental: Arm C
|
Specified dose on specified days
Specified dose on specified days
|
|
Experimental: Arm D
|
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with Adverse Events (AE)
Time Frame: Up to Day 47
|
Up to Day 47
|
|
|
Number of participants with Serious Adverse Events (SAE)
Time Frame: Up to Day 47
|
Up to Day 47
|
|
|
Number of participants with Vital Sign Abnormalities
Time Frame: Up to Day 27
|
Up to Day 27
|
|
|
Number of participants with Physical Examination Abnormalities
Time Frame: Up to Day 27
|
Including neurological examination
|
Up to Day 27
|
|
Number of participants with Electrocardiogram (ECG) Abnormalities
Time Frame: Up to Day 27
|
Up to Day 27
|
|
|
Number of participants with Clinical Laboratory Assessments Abnormalities
Time Frame: Up to Day 27
|
Up to Day 27
|
|
|
Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Up to Day 27
|
Up to Day 27
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum observed concentration (Cmax)
Time Frame: Up to Day 26 from last dose
|
Up to Day 26 from last dose
|
|
|
Time of maximum observed concentration (Tmax)
Time Frame: Up to Day 26 from last dose
|
Up to Day 26 from last dose
|
|
|
Area under the concentration-time curve from Time Zero to Time of Last Quantifiable Concentration (AUC(0-T))
Time Frame: Up to Day 26 from last dose
|
Arm A, Arm B, and Arm C
|
Up to Day 26 from last dose
|
|
AUC from Time Zero Extrapolated to Infinite Time (AUC(INF))
Time Frame: Up to Day 26 from last dose
|
Arm A and Arm C
|
Up to Day 26 from last dose
|
|
AUC from Time Zero to 24 Hours (AUC(0-24))
Time Frame: Up to Day 9 from last dose
|
Arm A
|
Up to Day 9 from last dose
|
|
Elimination Half-Life (T-HALF)
Time Frame: Up to Day 26 from last dose
|
Arm A, Arm B, and Arm C
|
Up to Day 26 from last dose
|
|
Apparent Total Body Clearance from Plasma (CLT/F)
Time Frame: Up to Day 26 from last dose
|
Arm A, Arm B, and Arm C
|
Up to Day 26 from last dose
|
|
Apparent Volume of Distribution (Vz/F)
Time Frame: Up to Day 26 from last dose
|
Arm A, Arm B, and Arm C
|
Up to Day 26 from last dose
|
|
AUC in 1 dosing interval (AUC (TAU))
Time Frame: Up to Day 22 from last dose
|
Arm B, D
|
Up to Day 22 from last dose
|
|
Cerebrospinal fluid (CSF) concentrations
Time Frame: Up to Day 13
|
Arm B
|
Up to Day 13
|
|
Ratio of total and unbound CSF to plasma concentration
Time Frame: Up to Day 13
|
Arm B
|
Up to Day 13
|
|
Geometric mean ratio of Cmax
Time Frame: Up to Day 26 from last dose
|
Arm C, D
|
Up to Day 26 from last dose
|
|
Geometric mean ratio of AUC(0-T)
Time Frame: Up to Day 26 from last dose
|
Arm C, D
|
Up to Day 26 from last dose
|
|
Geometric mean ratio of AUC(INF)
Time Frame: Up to Day 26 from last dose
|
Arm C, D
|
Up to Day 26 from last dose
|
|
Cmax of dabigatran in plasma
Time Frame: Up to Day 18 from last dose
|
Arm D
|
Up to Day 18 from last dose
|
|
Cmax of rosuvastatin in plasma
Time Frame: Up to Day 20 from last dose
|
Arm D
|
Up to Day 20 from last dose
|
|
AUC(0-T) of dabigatran in plasma
Time Frame: Up to Day 18 from last dose
|
Arm D
|
Up to Day 18 from last dose
|
|
AUC(0-T) of rosuvastatin in plasma
Time Frame: Up to Day 20 from last dose
|
Arm D
|
Up to Day 20 from last dose
|
|
AUC(INF) of dabigatran in plasma
Time Frame: Up to Day 18 from last dose
|
Arm D
|
Up to Day 18 from last dose
|
|
AUC(INF) of rosuvastatin in plasma
Time Frame: Up to Day 20 from last dose
|
Arm D
|
Up to Day 20 from last dose
|
|
Tmax of dabigatran in plasma
Time Frame: Up to Day 18 from last dose
|
Arm D
|
Up to Day 18 from last dose
|
|
Tmax of rosuvastatin in plasma
Time Frame: Up to Day 20 from last dose
|
Arm D
|
Up to Day 20 from last dose
|
|
T-HALF of dabigatran in plasma
Time Frame: Up to Day 26 from last dose
|
Up to Day 26 from last dose
|
|
|
T-HALF of rosuvastatin in plasma
Time Frame: Up to Day 20 from last dose
|
Arm D
|
Up to Day 20 from last dose
|
|
CLT/F of dabigatran in plasma
Time Frame: Up to Day 18 from last dose
|
Arm D
|
Up to Day 18 from last dose
|
|
CLT/F of rosuvastatin in plasma
Time Frame: Up to Day 27 from last dose
|
Up to Day 27 from last dose
|
|
|
Vz/F of dabigatran in plasma
Time Frame: Up to Day 18 from last dose
|
Arm D
|
Up to Day 18 from last dose
|
|
Vz/F of rosuvastatin in plasma
Time Frame: Up to Day 20 from last dose
|
Arm D
|
Up to Day 20 from last dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Dyslipidemias
- Lipid Metabolism Disorders
- Lipid Metabolism, Inborn Errors
- Hypoalphalipoproteinemias
- Hypolipoproteinemias
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Lecithin Cholesterol Acyltransferase Deficiency
- Sulfur Compounds
- Organic Chemicals
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Benzimidazoles
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Thiazoles
- Azoles
- Hydrocarbons
- Amides
- Pyrimidines
- Hydrocarbons, Halogenated
- Sulfonamides
- Sulfones
- Fluorobenzenes
- Hydrocarbons, Fluorinated
- Dabigatran
- Rosuvastatin Calcium
- Famotidine
Other Study ID Numbers
Other Study ID Numbers
- CN016-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.